105 related articles for article (PubMed ID: 2362454)
1. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--I. General findings.
Lundgren S; Lønning PE; Utaaker E; Aakvaag A; Kvinnsland S
J Steroid Biochem; 1990 Jun; 36(1-2):99-104. PubMed ID: 2362454
[TBL] [Abstract][Full Text] [Related]
2. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--II. A differential effect of megestrol acetate and medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin.
Lundgren S; Lønning PE
J Steroid Biochem; 1990 Jun; 36(1-2):105-9. PubMed ID: 2141886
[TBL] [Abstract][Full Text] [Related]
3. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
4. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.
Lundgren S; Lønning PE; Aakvaag A; Kvinnsland S
Cancer Chemother Pharmacol; 1990; 27(2):101-5. PubMed ID: 2249324
[TBL] [Abstract][Full Text] [Related]
5. Studies on the role of intestinal bacteria in metabolism of synthetic and natural steroid hormones.
Adlercreutz H; Pulkkinen MO; Hämäläinen EK; Korpela JT
J Steroid Biochem; 1984 Jan; 20(1):217-29. PubMed ID: 6231418
[TBL] [Abstract][Full Text] [Related]
6. Adrenal steroids as parameters of the bioavailability of MA and MPA.
Willemse PH; Dikkeschei LD; Tjabbes T; van Veelen H; Sleijfer DT
Eur J Cancer; 1990 Mar; 26(3):359-62. PubMed ID: 2141494
[TBL] [Abstract][Full Text] [Related]
7. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
[TBL] [Abstract][Full Text] [Related]
8. Progestins in breast cancer treatment. A review.
Lundgren S
Acta Oncol; 1992; 31(7):709-22. PubMed ID: 1476750
[TBL] [Abstract][Full Text] [Related]
9. Oral high-dose progestins as treatment for advanced breast cancer.
Lundgren S; Kvinnsland S; Utaaker E
Acta Oncol; 1989; 28(6):811-6. PubMed ID: 2532917
[TBL] [Abstract][Full Text] [Related]
10. The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.
Dowsett M; Lal A; Smith IE; Jeffcoate SL
Br J Cancer; 1987 Mar; 55(3):311-3. PubMed ID: 2952154
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women.
Adly L; Hill D; Sherman ME; Sturgeon SR; Fears T; Mies C; Ziegler RG; Hoover RN; Schairer C
Int J Cancer; 2006 Nov; 119(10):2402-7. PubMed ID: 16894564
[TBL] [Abstract][Full Text] [Related]
12. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
van Veelen H; Willemse PH; Sleijfer DT; Sluiter WJ; Doorenbos H
Cancer Treat Rep; 1985 Sep; 69(9):977-83. PubMed ID: 3161613
[TBL] [Abstract][Full Text] [Related]
13. Changes in serum sex steroid levels during megestrol acetate therapy.
Pommier RF; Woltering EA; Fletcher WS
Surg Oncol; 1994 Dec; 3(6):351-9. PubMed ID: 7773452
[TBL] [Abstract][Full Text] [Related]
14. The influence of progestins on receptor levels in breast cancer metastasis.
Lundgren S; Kvinnsland S; Varhaug JE; Utaaker E
Anticancer Res; 1987; 7(1):119-23. PubMed ID: 3032071
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent.
Jeppsson S; Gershagen S; Johansson ED; Rannevik G
Acta Endocrinol (Copenh); 1982 Mar; 99(3):339-43. PubMed ID: 6461995
[TBL] [Abstract][Full Text] [Related]
16. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
17. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer.
Willemse PH; van der Ploeg E; Sleijfer DT; Tjabbes T; van Veelen H
Eur J Cancer; 1990 Mar; 26(3):337-43. PubMed ID: 2141491
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of estrogens, sex hormone binding globulin, and androgens and risk of breast hyperplasia in postmenopausal women.
Schairer C; Hill D; Sturgeon SR; Fears T; Mies C; Ziegler RG; Hoover RN; Sherman ME
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1660-5. PubMed ID: 16030098
[TBL] [Abstract][Full Text] [Related]
19. Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin.
Kraemer GR; Kraemer RR; Ogden BW; Kilpatrick RE; Gimpel TL; Castracane VD
Fertil Steril; 2003 Mar; 79(3):534-42. PubMed ID: 12620436
[TBL] [Abstract][Full Text] [Related]
20. Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects.
Alexieva-Figusch J; Blankenstein MA; Hop WC; Klijn JG; Lamberts SW; de Jong FH; Docter R; Adlercreutz H; van Gilse HA
Eur J Cancer Clin Oncol; 1984 Jan; 20(1):33-40. PubMed ID: 6363095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
